Physician

Emerson A Lim, M.D.

According to 2025 Medicare claims, Emerson Lim, M.D. (NPI: 1407030307) practices medical oncology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Kent, MI. This provider's primary affiliated billing organization is SPECTRUM HEALTH PRIMARY CARE PARTNERS (NPI: 1235188673; TIN: 381358164) and primary practice location at 49503-2565. Lim is affiliated with the NewYork Quality Care (ACO ID: A2571), Trinity Health Integrated Care (ACO ID: A3454), and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Lim's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 159 traditional Medicare patients, billed 458 HCPCS/CPT codes, and received $33,952 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,944 prescription claims across 252 beneficiaries totaling $4,581,004 in drug costs, led by Abiraterone Acetate (Abiraterone Acetate). 2021 DME data shows 24 claims. Open Payments data shows 28 records totaling $1,040,551. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $71,777 to $33,952. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,260,455 and ending at $4,581,004. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $177 to $855.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	117	685	$71,777
2016	138	1,067	$128,063
2017	149	1,344	$166,735
2018	140	1,122	$131,198
2019	136	918	$106,183
2020	136	1,006	$120,650
2021	119	804	$100,906
2022	91	346	$30,048
2023	149	541	$43,184
2024	159	458	$33,952

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	79	518	$1,260,455
2016	97	770	$1,817,080
2017	96	765	$2,634,620
2018	93	874	$3,711,444
2019	109	929	$4,220,998
2020	100	797	$3,252,295
2021	91	607	$1,483,793
2022	113	461	$1,171,133
2023	203	1,353	$3,483,042
2024	252	1,944	$4,581,004

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	22	$720
2021	N/R	24	$861
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	20	20	$102
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	23	23	$100
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	146	339	$72
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	14	19	$57
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	17	17	$44

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Abiraterone Acetate	Abiraterone Acetate	504	15,300	$1,803,111
Xtandi	Enzalutamide	48	1,440	$686,456
Cabometyx	Cabozantinib S-Malate	21	630	$535,390
Inlyta	Axitinib	31	902	$529,055
Welireg	Belzutifan	11	330	$236,314

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$23	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	27	$1,040,528	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Emerson A. Lim, M.D.?

Tedicare shows public-source Medicare data for Emerson A. Lim, M.D. (NPI 1407030307), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Emerson A. Lim, M.D. have ACO affiliation data?

Emerson A. Lim, M.D. is shown with ACO affiliation data for NewYork Quality Care (MSSP, ACO ID A2571), Trinity Health Integrated Care (MSSP, ACO ID A3454), and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Emerson A. Lim, M.D.?

Emerson A. Lim, M.D. is linked to SPECTRUM HEALTH PRIMARY CARE PARTNERS (billing NPI 1235188673) in the available physician profile data.

Does Emerson A. Lim, M.D. have Open Payments data?

Emerson A. Lim, M.D. has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.